Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure

被引：10

作者：

Lehtonen L. ^{[1
]}

机构：

[1] Department of Clinical Pharmacology, University of Helsinki, Helsinki University Central Hospital, Haartmaninkatu 4

来源：

Current Cardiology Reports | 2000年 / 2卷 / 3期

关键词：

Heart Failure; Dobutamine; Pulmonary Capillary Wedge Pressure; Levosimendan; Milrinone;

D O I：

10.1007/s11886-000-0074-6

中图分类号：

学科分类号：

摘要：

Levosimendan is a new inodilator, whose mechanism of action includes calcium sensitization of contractile proteins and the opening of ATP-dependent potassium channels. The combination of positive inotropy with anti-ischemic effects of K-channel opening offers many potential benefits in comparison to currently available intravenous inotropes, that are more or less contraindicated in patients with ongoing myocardial ischemia. Levosimendan has been extensively studied in various animal models of heart failure, in which the drug has increased contractility without adverse effects on diastolic function. These results have been repeated in patients with heart failure, by whom levosimendan dose-dependently increases cardiac output and reduces pulmonary capillary wedge pressure. On higher doses, the drug can induce tachycardia and hypotension. In clinical trials, drug-induced ventricular arrhythmia have been rare. Recently, trials in patients with decompensated heart failure have suggested that short-term intravenous treatment with levosimendan might improve the survival of these critical patients. These results highlight the importance of adequate treatment of the acute heart failure patients for their long-term outcome. Copyright © 2000 by Current Science Inc.

引用

页码：233 / 243

页数：10

共 75 条

[1]

Packer, M., Carver, J.R., Rodeheffer, R.J., Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group (1991) N Engl J Med, 325, pp. 1468-1475

[2]

Cohn, J.N., Goldstein, S.O., Greenberg, B.H., A dosedependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators (1998) N Engl J Med, 339, pp. 1810-1816

[3]

Leier, C.V., Binkley, P.H., Parenteral inotropic support for advanced congestive heart failure (1998) Prog Cardiovasc Dis, 41, pp. 207-224

[4]

Du Toit, E.F., Muller, C.A., McCarthy, J., Opie, L.H., Levosimendan: Effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart (1999) J Pharmacol Exp Ther, 290, pp. 505-514

[5]

Ver Donck, L., Calcium-sensitizing drugs: Positive inotropy by enhanced sensitivity of the contractile apparatus to calcium (1996) Cardiovasc Drug Rev, 14, pp. 185-212

[6]

Feldman, A.M., Classification of positive inotropic agent (1993) J Am Coll Cardiol, 22, pp. 1223-1227

[7]

Haikala, H., Lindén, I.-B., Mechanisms of action of calciumsensitizing drugs (1995) J Cardiovasc Pharmacol, 1 (SUPPL. 1), pp. S10-S19

[8]

Pollesello, P., Ovaska, M., Kaivola, J., Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C (1994) J Biol Chem, 269, pp. 28584-28590

[9]

Haikala, H., Kaivola, J., Nissinen, E., Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan (1995) J Mol Cell Cardiol, 27, pp. 1859-1866

[10]

Haikala, H., Nissinen, E., Etemadzadeh, E., Troponin Cmediated calcium sensitization induced by levosimendan does not impair relaxation (1995) J Cardiovasc Pharmacol, 25, pp. 794-801

← 1 2 3 4 5 6 7 8 →